Verrica says post-hoc Phase 3 analysis shows YCANTH clears molluscum regardless of disease duration

Reuters2026/09/10 12:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Verrica Pharmaceuticals scheduled new posters on YCANTH and VP-315 for September 2026 dermatology conferences.
YCANTH post-hoc Phase 3 analysis will be presented publicly for the first time, showing strong clearance regardless of molluscum duration.
Findings support broader use versus watchful waiting, potentially expanding treating-physician confidence and eligible patient capture.
VP-315 encore poster repeats previously presented Phase 2 exploratory data suggesting immune-driven shrinkage in untreated basal cell carcinoma lesions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100805PRIMZONEFULLFEED9824224) on September 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Verrica says post-hoc Phase 3 analysis shows YCANTH clears molluscum regardless of disease duration

You may also like

Crypto prices